Amwill Healthcare
CLOSEDIPO Date: 5 Feb - 7 Feb 2025
Listing Date: 12 Feb 2025
Price Range
₹105 – ₹111
Issue Size
60 Cr
Min Investment
₹1,26,000
Lot Size
1200 Shares
Schedule of Amwill Healthcare
Issue open date
5 Feb 2025
Issue close date
7 Feb 2025
UPI mandate deadline
7 Feb 2025 (5 PM)
Allotment finalization
10 Feb 2025
Share credit
11 Feb 2025
Listing date
12 Feb 2025
Mandate end date
20 Feb 2025
Issue size
| Funds Raised in the IPO | Amount |
|---|---|
| Overall | 60 Cr |
| Fresh Issue | 48.88 Cr |
| Offer for Sale | 11.1 Cr |
Allotment DetailsNew
| Allotment Timeline | Details |
|---|---|
| Allotment Date | 10 Feb 2025 |
| Allotment Link | {Link} |
Grey Market PremiumNew
Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.
| Date | Ipo Price | GMP | Estimated Listing Price |
|---|---|---|---|
| 12 Feb 2025 | ₹111 | ₹-9 | ₹102 (-8%) |
| 11 Feb 2025 | ₹111 | ₹-6 | ₹105 (-5%) |
| 10 Feb 2025 | ₹111 | ₹0 | ₹111 (0%) |
| 8 Feb 2025 | ₹111 | ₹0 | ₹111 (0%) |
| 7 Feb 2025 | ₹111 | ₹11 | ₹122 (9.91%) |
| 6 Feb 2025 | ₹111 | ₹11 | ₹122 (9.91%) |
| 5 Feb 2025 | ₹111 | ₹6 | ₹117 (5.41%) |
| 4 Feb 2025 | ₹111 | ₹14 | ₹125 (12.61%) |
| 3 Feb 2025 | ₹111 | ₹0 | ₹111 (0%) |
Performance Amwill Healthcare
| Issue Price | Listing Gain | Current Market Price | P/L |
|---|---|---|---|
| ₹105 – ₹111 | ₹ 93 (-19.95%) | ₹ 82.39 | -25.77% |
About Amwill Healthcare
Amwill Healthcare, a derma-cosmetic developer, focuses on innovative dermatological solutions by outsourcing manufacturing and distribution to enhance product formulation. Led by founder Anand Gandhi, the company specializes in both generic and specific skin treatments, with a significant presence in Karnataka, Andhra Pradesh, and Telangana. Amwill leverages expert insights from dermatologists to ensure high-quality, compliant products through partnerships with certified contract manufacturers. The company strategically uses its affiliate, Amderma Healthcare LLP, for streamlined storage and distribution, preparing for expansion into new regional markets.
| Founded in | 2017 |
| Managing director | Mr. Anand Gandhi and Mr. Tarun Gandhi |
| Parent organization | Amwill Healthcare Ltd |
Financial Overview
Strengths
- Specializes in derma-cosmetic solutions targeting a growing skincare market.
- Strong ties with dermatologists enhance product innovation and effectiveness.
- Outsourced manufacturing focuses resources on product development.
- Solid market presence in Karnataka, Andhra Pradesh, and Telangana supports expansion.
Risks
- No historical market for shares may lead to price volatility post-IPO.
- Dependency on third-party manufacturers risks quality and supply issues.
- Faces intense competition in a rapidly evolving skincare industry.
- Regulatory compliance risks could impact operations and finances.
Subscription Figures
| Category | Subscription (No. of times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 2.02 |
| Non-Institutional Investors (NIIs) | 0.31 |
| Retail Individual Investors (RIIs) | 0.75 |
| Employee | N/A |
| Total | 0.83 |